Home
  >  
Section 70
  >  
Chapter 69,351

Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer

Shahjehan, F.; Kamatham, S.; Ritter, A.; Kasi, P.M.

Clinical Case Reports 7(9): 1729-1734

2019


ISSN/ISBN: 2050-0904
PMID: 31534737
DOI: 10.1002/ccr3.2333
Accession: 069350632

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy, after progression postimmunotherapy, has shown a near-complete response in our patient with metastatic anal cancer. This likely is secondary to the sequence of immunotherapy followed by chemotherapy that is yielding greater than historical responses.

PDF emailed within 0-6 h: $19.90